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Abstract:  Inhibition  of  cytochrome  P450  (CYP)  is  a  major  cause  of  herb–drug 
interactions.  The  CYP1A2  enzyme  plays  a  major  role  in  the  metabolism  of  drugs  in 
humans.  Its  broad  substrate  specificity,  as  well  as  its  inhibition  by  a  vast  array  of 
structurally diverse herbal  active ingredients,  has indicated  the possibility of metabolic 
herb–drug interactions. Therefore nowadays searching inhibitors for CYP1A2 from herbal 
medicines are drawing much more attention by biological, chemical and pharmological 
scientists.  In  our  work,  a  pharmacophore  model  as  well  as  the  docking  technology  is 
proposed to screen inhibitors from herbal ingredients data. Firstly different pharmaphore 
models  were  constructed  and  then  validated  and  modified  by  202  herbal  ingredients. 
Secondly  the  best  pharmaphore  model  was  chosen  to  virtually  screen  the  herbal  data  
(a curated database of 989 herbal compounds). Then the hits (147 herbal compounds) were 
continued  to  be  filtered  by  a  docking  process,  and  were  tested  in  vitro  successively. 
Finally, five of eighteen candidate compounds (272, 284, 300, 616 and 817) were found to 
have inhibition of CYP1A2 activity.  The model developed in our study is efficient for 
in silico screening of large herbal databases in the identification of CYP1A2 inhibitors. It 
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will play an important role to prevent the risk of herb–drug interactions at an early stage of 
the drug development process. 
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1. Introduction  
During the last decade, North America and Europe have witnessed a drastic growth in the use of 
herbal medicine. In a comprehensive review on the usage of complementary and alternative medicine, 
16% of prescription drug users are reported to consume herbal supplements [1], two-thirds of women 
used  herbs  for  perimenopausal  symptoms,  45%  of  parents  gave  their  children  herbal  treatments  
and 45% of pregnant women tried herbal remedy  [2]. Meanwhile, some reports have indicated that 
more than 60% of patients use their herbal medicine with conventional medicines as usual [3]. Because 
some of constituents in herbal products may be substrates, inhibitors and/or inducers of the cytochrome 
P450 enzymes (CYPs) [4,5], thus could have an impact on the pharmacokinetics of a co-administered 
drug metabolized by the CYP enzymes, which will probably lead to the herb–drug interaction.  The 
most  well-known  example  of  an  herb–drug  interaction  is  St  John’s  wort,  which  could  cause  the 
clearance of CYP1A2 substrates such as theophylline [6]. Clinically significant interactions were also 
reported from the use of grapefruit juices in calcium antagonists, antihistamine and benzodiazepines 
treatment  [7–9]. Nowadays, the interaction of drugs with herbal medicines has become a significant 
safety concern, especially for drugs with narrow therapeutic indices.  
Among all of  these cytochrome P450 enzymes, CYP1A2 should attract more attention since it is 
one of the key enzymes with the important role in the metabolic clearance of 5% of currently marketed 
drugs [10]. Also it is involved in a number of clinical herb–drug interactions [11–13]. When herbal 
medicines are used with western medicines metabolized by CYP1A2 at the same time, it is necessary 
to know whether this herb medicine will inhibit CYP1A2 or not. This means that the prediction of 
herb–drug interactions in vitro is important and thus many herbal medicines were tested in vitro by 
scientists  [14–16].  However,  the  number  of  herbal  medicines  is  large.  Traditional  screening 
technologies such as testing each herbal medicine to enzyme in vitro or in vivo would not only be 
costly,  but  also  inefficient.  Recently,  several  attempts  in  the  application  of  computational  models  
for  CYP1A2  ligand  binding  have  been  reported,  reflecting  the  desire  of  early  identification  of  
CYP1A2 inhibitors [17–22]. Taesung Moon et al. [23] pioneered investigations on the quantitative 
structure-activity relationship  (QSAR)  of flavonoids and  their derivatives.  However, their samples 
were  only  flavonoids,  which  were  not  representative  of  all herb  ingredients  and  fail  to  accurately 
predict the inhibitory potencies of structurally unrelated herb ingredients. 
In  order  to  better  predict  herb–drug  interaction  as  well  as  select  rapid  inhibitors  from  herbal 
ingredients, a combinational pharmacophore model were presented to virtually screen the herb data 
before those candidate compounds were tested in vitro to determine their inhibitory effect on CYP1A2. 
The model developed here is efficient for virtual screening of large herbal databases for identification 
of CYP1A2 inhibitors, and it will play an important role to prevent the risk of herb–drug interactions at 
an early stage of the drug development process. Int. J. Mol. Sci. 2011, 12                       
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2. Results and Discussion 
2.1. Pharmacophore Models 
For the pharmacophore screening, the key step was to choose a good template molecule. In this 
study,  several  template  molecules  (Figure  1)  could  be  obtained  to  generate  the  pharmacophore:  
(1)  the  substrates  extracted  from  complex  structures  of  CYP1A2  and  its  homologous  enzymes;  
and (2) inhibitors reported in the literature [24]. Different template molecules based on individual or 
integrated information above were used to generate the pharmacophores. Then up to 202 different herb 
integrants  tested  in  vitro  by  our  group  were  used  as  the  test  dataset  (supplement  Table  2).  The 
molecular structure of selected template was shown in Figure 2. Finally,  the  pharmacophore  model 
was obtained (Figure 3). The true positive rate and true negative rate of the best pharmacophore model 
were  84.6%  (11/13)  and  86.8%  (164/189),  respectively.  Other  results  of  different  pharmacophore 
models are also shown in Table 1 as a comparison. 
Figure 1. Molecular structure of the template molecules used in this work. 
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Figure 2. The molecular structure of selected template by superposing three bifonazole in 
three different conformations. 
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Figure  3.  The  final  pharmacophore  of  CYP1A2.  F1–F3:  Aro|Hyd;  F4:  PiN;  
F5: Aro|PiN|Hyd|Cat|Acc|Don; V1: Exterior Volume; V2–V8: Excluded Volume. 
 
Table 1. The results of different pharmacophore models. 
Compounds Used as a Template  True Positive Rate  True Negative Rate 
BHF, TMI  61.5%  85.2% 
BHF, Chrysin and Tanshinone IIA  69.2%  96.8% 
Chrysin, Psoralen and Dracorhodin  61.5%  89.9% 
Three TMI in different conformations 
without optimization 
84.6%  77.2% 
Three TMI in different conformations with 
sophisticated optimization 
84.6%  86.8% 
There  were  still  disputes  on  how  to  superpose  these  template  molecul es  used  to  build  the 
pharmacophore [25]. It is known that there are two opinions on the active conformation [26–28]; some 
people prefer to optimize the energy of these template molecules and obtain the conformation with 
minimum  energy.  While  another  group  of  people  believe  that  the  docking  conformation  is  the  
active  conformation  and  these  template  molecules  extracted  from  the  crystal  structure  should  be 
superposed directly. Our results have shown that the latter opinion is more reasonable compared with 
the former one [29]. 
By observing the complex crystal structure of CYP1A2 and its homologous enzymes, we found that 
not only different substrates could exist in the same acceptor, but also different conformations of one 
substrate could exist within one complex crystal structure. It is obvious that superposing the different 
conformations of one substrate appearing in one complex crystal structure will be the best option, since 
these conformations were not only the true active conformation, but also reduces errors commonly Int. J. Mol. Sci. 2011, 12                       
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caused by trying different crystal structures, measurements and analysis conditions. As a validation, 
the results shown in Table 1 were proved by Zhao et al. recently [24]. 
In addition, our work also indicated that it was important to collect some negative data in the 
building of pharmacophore, since excluded volume of the pharmacophore was built on the negative 
data. Also the building of excluded volume is the key to increase the true negative rate. However, this 
step was often ignored by former research groups.  
Finally, 147 hits were filtered out by the selected pharmacophore model from 989 compounds, 
which were separated from various herbs collected in our group. Formerly, compounds in Chinese 
Nature Products Database (CNPD v.2004.1)  [30] were also screened by using this pharmacophore 
model. Unfortunately, this research had to be abandoned because hits in CNPD were unavailable. 
2.2. Docking Results 
Admittedly, two challenges in the field of molecular docking still exist: (1) ligand placement in 
active site, and (2) scoring of docked poses [31,32]. However, compared with the semi-quantitative 
method of the pharmacophore model, molecular docking, as one of the quantitative methods, is better 
for prioritizing the hits with the help of deriving stable docking parameters and combing. Recently, the 
work of Yu Chen and Brian K. Shoichet [33] reinforced more confidence to docking results. 
The purpose of the dock application is to search for favorable binding configurations between small 
to medium-sized ligands and a not too flexible macromolecular target, which is usually a protein. For 
each ligand, a number of configurations called poses are generated and scored in an effort to determine 
favorable binding modes. Optionally, poses can be constrained to fit a pharmacophore query. The top 
scoring poses are written to a database for further analysis.  
In addition, 147 compounds formerly filtered from the pharmacophore model were docked into the 
active site of CYP1A2. For comparison, docking was run twice and results are presented in supplement 
Table 1. It can be seen that this set of docking parameters almost produced stable docking results. 
Finally, the same hits appearing in the top 20 of both results were chosen. Thus, up to 18 hits 
(Figure 4) were filtered into the next in vitro screening. 
Figure 4. Molecular structure of 18 compounds tested in vitro. 
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Figure 4. Cont. 
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2.3. In Vitro Testing 
A total of 18 candidate compounds selected by pharmacophore and docking were examined for 
their potential to inhibit rhCYP1A2 phenacetin O-deethylation activity at a test concentration of 1 μM. 
The results of in vitro testing were listed in Table 2. Five of 18 test compounds (272, 284, 300, 616 
and 817) were confirmed to have inhibitory activities to CYP1A2. The model was validated by the 
in vitro experiment where accuracy was 27.8% (5/18).  Int. J. Mol. Sci. 2011, 12                       
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In this study, 971 herbal compounds were excluded by virtual screen and the exclusion rate was 
98.2%. The high exclusion rate for screening larger database was very helpful, since it is not only 
time-saving and economic, but also helps to improve the success rate of screening test in vitro. The 
high exclusion rate also could help to reduce the number of candidate compounds in CNPD and make 
the experiment more goal-oriented. 
In the present study, two of five test compounds which inhibited CYP1A2 activities were flavonoid 
compounds. In the early experiment, five of 13 herb compounds which inhibited CYP1A2 activities 
were flavonoid compounds. The flavonoid compounds accounted for almost 40% (7/18) of the total of 
all  inhibitors.  This  show  that  the  potential  for  flavonoid  inhibited  CYP1A2  has  tremendous 
possibilities. The ability of flavonoids to inhibit CYP1A2 has been extensively confirmed [34,35]. 
Flavones are present in a wide variety of fruits and vegetables whereas flavones are mainly found in 
cereals and herbs [35–37]. In some countries flavonoids are commonly used as therapeutic agents and 
some flavonoids are administered orally or intravenously as drugs [38,39]. However, there was little 
awareness of the potential for flavonoid interactions with conventional drugs. Some clinical studies 
have demonstrated that flavonoids can affect the metabolism of other drugs [39–41]. Accordingly, 
flavonoids’ effect on the activity of CYP1A2 should be given more attention. Other herb compounds 
were also selected using the pharmacophore model and it was validated that they inhibited CYP1A2 
activities  in  vitro.  Compound  300  was  a  coumarins  compound  and  compound  284  and  616  were 
lignanoids compounds.  
Table 2. Results of in vitro testing. 
Number  Active Ingredients 
% of Control 
Indication Activity 
zhang 9  5-hydroxy-7-methoxycoumarin-8-O-D-glucopyranoside  >90% 
zhang 83  rhamnetin 3-O-β-D-galactopyranoside  >90% 
zhang 84  rhamnetin 3-O-β-D-glucopyranoside  >90% 
zhang 89  1,6,8-trihydroxy-2,3-methylenedioxy-5-geranylxanthone  >90% 
zhang 205  quercetin-3-O-β-D-arabinopyranoside  >90% 
zhang 206  quercetin-3-O-α-D-arabinofuranose  >90% 
zhang 210  dihydrokaempferol-3-O-α-D-arabinofuranose  >90% 
zhang 271  5'-demethoxy Daphneticin  >90% 
zhang 272  3'-hydroxy-Genkwanin  <90% 
zhang 284  (−)-Matairesinol  <90% 
zhang 300  Edgeworthin  <90% 
zhang 445  Hemiphloin  >90% 
zhang 616  (+)-Matairesinol  <90% 
zhang 713  Piceid  >90% 
zhang 759  3,3',4'-Tri-Me ether-3,3',4',5,7-Pentahydroxyflavone  >90% 
zhang 779  (−)-Threo-guaiacylglycerol-8-O-4'-(coniferyl alcohol) ether  >90% 
zhang 817  Spinacetin  <90% 
zhang 911  Kaempferol-3-O-α-L-rhamnopyranoside  >90% 
Note: Values represent the average of duplicate determinations. Values in italics represent those exhibiting 
10% inhibition or greater. Int. J. Mol. Sci. 2011, 12                       
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3. Materials and Methods 
A tandem workflow is designed to screen the inhibitors of CYP1A2 from natural compounds. This 
workflow is outlined in Figure 5. Details are listed below: Our analysis was started by constructing the 
pharmaphore model of CYP1A2. The 3D structures of CYP1A2, its homologues and several reported 
inhibitors of CYP1A2 were used to test the basic templates. Then up to 202 herb ingredients tested 
in vitro were used to validate and modify the basic templates to derive the most suitable pharmaphore 
model of CYP1A2. In the following, based on the 3D structures of CYP1A2, an active site for docking 
was chosen as a complementary process for further screening. Finally, compounds having passed the 
former filters were tested in vitro.  
Figure 5. General workflow used in our study. 
 
3.1. Pharmacophore Generation 
The crystal structure of CYP1A2 and its homologue CYP2B4 were retrieved from the Protein Data 
Bank (PDB code 2HI4 [42] and 2BDM [20], respectively). The endogenic ligands α-naphthoflavone 
(BHF) and bifonazole (TMI) of those two crystals and several reported inhibitors of CYP1A2 were 
collected as the template molecules to train the pharmacophore model. 202 herb ingredients tested 
in vitro were used as the test dataset.  
The purpose of pharmacophore searching is to facilitate 3D searches of conformation databases 
using  molecule  annotations  related  to  ligand-receptor  binding  (like,  H-bond  donor,  acceptor, 
hydrophobe, etc.). A pharmacophore is a set of structural features in a ligand that are related to the 
ligand’s recognition at a receptor site and its biological activity. In Molecular Operation Environment 
(MOE)  [43]  pharmacophoric structural  features are represented by labeled points  in  space  with  a 
conformation of the ligand. Each ligand conformation is assigned a set of annotation points, which is a 
set  of  structural  features  that  may  contribute  to  the  ligand’s  pharmacophore.  A  database  of 
conformations can be searched with a query that represents a pharmacophore hypothesis. The result of Int. J. Mol. Sci. 2011, 12                       
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such  a  search  is  a  set  of  matches  that  align  the  pharmacophoric  features  of  the  query  to  the 
pharmacophoric features present in the ligands of the searched database. 
3.2. Docking Procedure 
The crystal structure of CYP1A2 (PDB code 2HI4) was used to derive the active site and tune the 
stable parameters in docking. 
MOE-Dock 2008.10 [43] function was used for docking. Ligand placement was performed using 
alpha sphere triangle matching, with London dG scoring. The top 30 hits were retained and refined 
using MMFF94X force field energy minimization with Generalized Born solvation model, allowing 
the receptor residues within 9 Å to relax around the mobile ligand. The active site of receptor’s side 
chains were tethered with a force constant of 1.0 kcal/(mol Å
2). Energy minimization was stopped 
when the root-mean-squared gradient cutoff of 0.0001 kcal/(mol Å) was reached. Final poses were 
ranked using the London dG method to calculate the free energy of binding. With this set of docking 
parameters, the crystallographic placement of α-naphthoflavone was accurately predicted in the crystal 
structure of Human Microsomal P450 1A2 receptor crystal structure, PDB: 2HI4 (Resolution (Å): 1.95) 
(Figure  6),  with  a  root-mean-squared  deviation  (RMSD)  of  0.3061  Å  and  a  binding  energy  of 
−11.1076 kcal/mol. 
Figure 6. Crystallographic (Red) and  docked (Blue) conformations of α-naphthoflavone  
in  the  Human  Microsomal  P450  1A2  receptor  site  S  =  −11.1076,  rmsd  =  0.3061.  
Note: Hydrogen bond is indicated by the pink dashed line. 
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3.3. Enzyme and Inhibition Assays 
The basic incubation medium contained 100 mM potassium phosphate buffer (PH 7.4), 50 pmol 
recombinant human CYP1A2, 25 μM phenacetin and 1 μM active ingredients. The final incubation 
volume was 200 μL. After 5 min pre-incubation at 37 ° C, the reaction was initiated by the addition of 
NADPH-generating system (5 mM MgCl2, 10 mM glucose 6-phosphates, 1 mM NADPH, and 2.5 U 
per  mL  glucose  6-phosphate  dehydrogenase).  Incubations  were  performed  in  a  37 ° C  shaking  
water  bath  for  1  h.  Reactions  were  stopped  by  adding  0.4  mL  of  ice-cold  acetonitrile  containing  
0.2 mg/L tinidazole (IS). Then 0.6 mL water was added to the mixture, vortex-mixing for 1.0 min and 
centrifuged  at  10,000  g  for  5  min,  and  separation  for  the  supernatants  were  performed  on  a  
ZORBAX SB-C18 column (3.5 μm, 2.1 ￗ 100 mm, Agilent Corporation, MA, USA) and a C18 guard 
column (5 μm, 4.0 ￗ 2.0 mm, Phenomenex, CA, USA) with an isocratic elution of acetonitrile—0.1% 
formic acid (35:65, v/v) at a flow rate of 0.3 ml/min for the amount of metabolite (acetaminophen) 
formed. The column was maintained at 35 ° C and the injection volume was 10 μL. The retention times 
of  paracetamol  and  tinidazole  were  1.872  and  3.912  min,  respectively.  The  percent  of  metabolic 
activity remaining was calculated by comparing the enzyme activities in the control samples that did 
not contain active ingredients. The active ingredient demonstrating 10% or greater inhibition at 1 μM 
was considered to have inhibitory activity. Each set of incubation was carried out with four control 
samples that contained no active ingredients. 
4. Conclusions  
In  this  study,  we  have  selected  several  template  molecules  to  generate  pharmacophores.  
202 different herb compounds were used as test data to test their inhibitory activity against CYP1A2  
in  vitro  and  used  to  identify  the  best  pharmacophore  with  the  highest  external  predictive  power.  
A highly predictive pharmacophore model was generated with three bifonazole (TMI)  in  different 
conformations with sophisticated optimization. A rigorously validated pharmacophore model was then 
used to screen our in-house database collection of a total of over one thousand herb compounds.  
147 hits were filtered out by the selected pharmacophore model and were docked into the active site of 
CYP1A2.  Finally,  18  hits  were  further  filtered  and  experimentally  validated.  Five  of  them  were 
confirmed to have inhibitory activities to CYP1A2, and the accuracy of the model was 27.8%. This 
study illustrates that the model developed here is efficient for virtual screening of large databases in 
the  identification  of  CYP1A2  inhibitors  or  non-inhibitors.  Accordingly,  the  models  can  play  an 
important role to prevent the risk of e.g., herb–drug interactions through metabolism at an early stage 
of the drug development process. 
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